文献速递垂体与肾上腺疾病性腺与生殖内分泌

经典先天性肾上腺皮质增生症青春期前抗雄激素、芳香化酶抑制剂及减少氢化可的松治疗后的成年身高

Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

一项开放随机对照试验将62例经典先天性肾上腺皮质增生症(CAH)儿童随机分为青春期前抗雄激素+芳香化酶抑制剂+减少氢化可的松+氟氢可的松联合方案组或标准治疗组,45例完成研究。两组成年身高SDS无显著差异(-0.34 vs -0.60,均差0.26,95%CI -0.29~0.82,P=.35),联合方案不推荐;女孩青春期继续抗雄激素可能获益。

要点

  • 青春期前联合方案未使成年身高SDS优于标准治疗(-0.34 vs -0.60,P=.35)。
  • 联合方案组青春期前生长速率和骨成熟速率降低,氢化可的松剂量更低(7.6 vs 15.0 mg/m2/天)。
  • 女孩青春期抗雄激素治疗允许更低糖皮质激素剂量并改善身高结局(成年身高减遗传靶身高 -0.7 vs -5.6 cm)。

核心结论

  • 青春期前抗雄激素、芳香化酶抑制剂联合减少氢化可的松可改善CAH患儿短期预测身高,但成年身高不高于标准治疗,不推荐该方案。
  • 女孩青春期抗雄激素治疗可能获益。

研究设计与样本

  • 开放、随机、对照试验,纳入62例经典CAH儿童,随机分为青春期前联合方案组(抗雄激素、芳香化酶抑制剂、减少氢化可的松、氟氢可的松)或标准治疗组(氢化可的松、氟氢可的松),女孩青春期继续抗雄激素,45例完成研究,主要终点为成年身高。

主要发现

  • 成年身高SDS联合方案组-0.34(0.93) vs 标准治疗组-0.60(0.89),均差0.26(95%CI -0.29, 0.82),P=.35,与遗传靶身高无关。
  • 两组成年身高均高于治疗前预测成年身高(P<.001)。
  • 青春期前联合方案组生长速率和骨成熟速率降低,氢化可的松剂量7.6(1.5) vs 15.0(3.6) mg/m2/天,P<.001。
  • 青春期开始时预测成年身高改善联合方案组大于标准治疗组(P=.049)。
  • 女孩青春期抗雄激素治疗允许更低糖皮质激素剂量,成年身高减遗传靶身高联合方案组-0.7(4.6) vs 标准治疗组-5.6(5.2) cm,均差4.9(95%CI 0.09, 9.7),P=.046。

临床怎么用

  • 作者认为青春期前抗雄激素、芳香化酶抑制剂联合减少氢化可的松不推荐用于改善成年身高。
  • 作者认为女孩青春期抗雄激素治疗可能获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Height outcome in patients with classic congenital adrenal hyperplasia (CAH) is suboptimal due to glucocorticoid and androgen excess. METHODS: In an open, randomized, controlled trial, children with classic CAH were randomized to receive a combination regimen of antiandrogen, aromatase inhibitor, reduced hydrocortisone, and fludrocortisone prior to puberty or standard therapy (hydrocortisone, fludrocortisone). Females continued on antiandrogen during puberty. The primary endpoint was adult height. RESULTS: Of 62 children randomized, 45 completed the study. Adult height SDS did not differ between the investigational and control groups (-0.34 [0.93] vs -0.60 [0.89], respectively), mean difference 0.26 [95% CI -0.29, 0.82], P = .35), irrespective of midparental height, but was greater than the predicted adult height pretreatment in both groups (P < .001). Growth rate and rate of bone maturation were reduced in the investigational group prior to puberty, despite lower hydrocortisone dose (7.6 [1.5] vs 15.0 [3.6] mg/m2/day, P < .001), and improvement in predicted adult height appeared greater at pubertal onset (P = .049) compared to standard therapy. Antiandrogen treatment during puberty in girls allowed for lower-dose glucocorticoid, and improved height outcome (adult minus midparental height: -0.7 [4.6] vs -5.6 [5.2] cm, mean difference 4.9 [95% CI 0.09, 9.7], P = .046). Those who received GnRHa had lower growth rate (P = .023) and longer years of unchanged bone age (P = .017), regardless of treatment. CONCLUSION: Prepubertal antiandrogen, aromatase inhibitor combination with reduced hydrocortisone improves short-term predicted height for children with CAH but does not result in taller adult stature than those treated with standard therapy, and is not recommended. Females may benefit from antiandrogen treatment during puberty.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Merke DP, Mallappa A, Parker M, et al. Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH. J Clin Endocrinol Metab. 2025. PMID: 39672600. doi:10.1210/clinem/dgae824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。